TRCT
DWTX

Tower Research Capital (TRC)’s Dogwood Therapeutics DWTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.98K Sell
3,093
-4,974
-62% -$8.24K ﹤0.01% 4321
2026
Q1 		$17K Buy
+8,067
New +$23.7K ﹤0.01% 3594
2025
Q4 		– Sell
-744
Closed -$5.73K – 5719
2025
Q3 		$5.73K Sell
744
-48
-6% -$239 ﹤0.01% 4206
2025
Q2 		$3.78K Sell
792
-258
-25% -$1.25K ﹤0.01% 4436
2025
Q1 		$5.26K Buy
1,050
+78
+8% +$528 ﹤0.01% 4138
2024
Q4 		$2.42K Buy
972
+699
+256% +$2.31K ﹤0.01% 4845
2024
Q3 		$1.16K Sell
273
-2
-0.7% -$10 ﹤0.01% 5197
2024
Q2 		$1.48K Buy
275
+3
+1% +$26 ﹤0.01% 5153
2024
Q1 		$3.26K Buy
272
+4
+1% +$45 ﹤0.01% 4895
2023
Q4 		$3.85K Sell
268
-83
-24% -$1.4K ﹤0.01% 5035
2023
Q3 		$8.11K Buy
351
+260
+286% +$9.04K ﹤0.01% 4390
2023
Q2 		$3.15K Buy
+91
New +$2.6K ﹤0.01% 5101
2022
Q3 		– Sell
-59
Closed -$6K – 6571
2022
Q2 		$6K Sell
59
-46
-44% -$4.81K ﹤0.01% 4969
2022
Q1 		$12K Buy
105
+104
+10,400% +$15.1K ﹤0.01% 4109
2021
Q4 		$0 Sell
1
-95
-99% -$12.1K ﹤0.01% 6649
2021
Q3 		$13K Buy
96
+35
+57% +$4.84K ﹤0.01% 4108
2021
Q2 		$10K Buy
61
+33
+118% +$4.68K ﹤0.01% 4407
2021
Q1 		$4K Buy
+28
New +$4.87K ﹤0.01% 4817

Other funds holding DWTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s DWTX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Dogwood Therapeutics (DWTX) stake by 62% in Q2 2026, selling an estimated $8.24K and leaving 3,093 shares worth $4.98K. The position accounts for ﹤0.01% of the portfolio, ranked #4321.

Tower Research Capital (TRC) first reported a position in DWTX in Q1 2021 and has held it in 18 quarters since. The position peaked at $17K in Q1 2026. 15 funds tracked by Wall St. Rank hold DWTX as of Q2 2026.

  • Tower Research Capital (TRC) held 3,093 shares of Dogwood Therapeutics worth $4.98K as of Q2 2026.
  • Tower Research Capital (TRC) sold 4,974 Dogwood Therapeutics shares in Q2 2026, an estimated $8.24K.
  • Dogwood Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4321 holding.
  • Tower Research Capital (TRC) first reported a position in Dogwood Therapeutics in Q1 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Dogwood Therapeutics position peaked at $17K in Q1 2026.
  • 15 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.